SinoMab BioScience Limited (HKG:3681)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.930
+0.030 (1.58%)
At close: Mar 10, 2026
60.83%
Market Cap 2.63B
Revenue (ttm) 6.28M
Net Income (ttm) -158.16M
Shares Out 1.39B
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,834,800
Average Volume 6,839,630
Open 1.930
Previous Close 1.900
Day's Range 1.910 - 1.980
52-Week Range 1.050 - 3.760
Beta 0.61
RSI 57.72
Earnings Date Mar 25, 2026

About SinoMab BioScience

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03 (Suciraslimab), a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 61
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3681
Full Company Profile

Financial Performance

In 2024, SinoMab BioScience's revenue was 2.03 million, an increase of 48.42% compared to the previous year's 1.37 million. Losses were -185.14 million, -23.85% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.